Key result
Simultaneous administration of the EV71 vaccine and trivalent influenza vaccine in infants aged 6-7 months achieved a 98.26% EV71 seroconversion rate, comparable to EV71 vaccination alone, with no significant difference in adverse events.
Why the study?
The study was conducted to assess the immunogenicity and safety of the enterovirus 71 vaccine (Vero cell) and trivalent split-virion influenza vaccine.
Does simultaneous administration of EV71 vaccine and IIV3 maintain immunogenicity and safety compared to separate administration in healthy infants aged 6-7 months?
RCT (n=378)
Open-label
Block randomization
Yes
Does simultaneous administration of EV71 vaccine and IIV3 maintain immunogenicity and safety compared to separate administration in healthy infants aged 6-7 months?
Coadministration of EV71 and influenza vaccines in infants is safe and does not compromise the immunogenicity of either vaccine.
Answers are grounded in this paper and cite their sources.
Supports coadministration of EV71 and IIV3 in infants; extends evidence for streamlined schedules without added risk.
Objective: To assess the immunogenicity and safety of the enterovirus 71 vaccine (Vero cell) (EV71 vaccine) and trivalent split-virion influenza vaccine (IIV3). Methods: Healthy infants aged 6–7 months were recruited from Zhejiang Province, Henan Province, and Guizhou Province and randomly assigned to the simultaneous vaccination group, EV71 group, and IIV3 group at a ratio of 1:1:1. Then, 3 mL blood samples were collected before vaccination and 28 days after the second dose of vaccine. Cytopathic effect inhibition assay was used to detect EV71 neutralization antibody, and cytopathic effect inhibition assay was used to detect influenza virus antibody. Results: A total of 378 infants were enrolled and received the first dose of vaccine and were included in the safety analysis, and 350 infants were involved in the immunogenicity analysis. The adverse events rates were 31.75%, 28.57%, and 34.13% in the simultaneous vaccination group, EV71 group, and IIV3 group (p > 0.05), respectively. No vaccine-related serious adverse events were reported. After two doses of EV71 vaccine, the seroconversion rates of EV71 neutralizing antibody were 98.26% and 97.37% in the simultaneous vaccination group and the EV71 group, respectively. After two doses of IIV3, the simultaneous vaccination group and the IIV3 group, respectively, had seroconversion rates of 80.00% and 86.78% for H1N1 antibody, 99.13% and 98.35% for H3N2 antibody, and 76.52% and 80.99% for B antibody. There was no statistically significant difference in the seroconversion rates of influenza virus antibodies between groups (p > 0.05). Conclusions: The coadministration of EV71 vaccine and IIV3 has good safety and immunogenicity in infants aged 6–7 months.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2023) conducted an RCT in Healthy infants (n=378). EV71 vaccine and Trivalent Split-Virion Influenza Vaccine (IIV3) coadministration vs. EV71 vaccine alone or IIV3 alone was evaluated on Seroconversion rate of EV71 neutralizing antibody (p=0.643). Simultaneous administration of the EV71 vaccine and trivalent influenza vaccine in infants aged 6-7 months achieved a 98.26% EV71 seroconversion rate, comparable to EV71 vaccination alone, with no significant difference in adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: